Andrew P. Levy

13.0k citations

179 papers · 9.9k indexed · 4 hit papers · h-index 50

Molecular Biology top 1%
Cell Biology top 0.2%
Cancer Research top 0.5%
Physiology top 1%
Surgery top 2%

Co-authors: Nina S. Levy Mark A. Goldberg Scott A. Wegner Rabea Asleh Rachel Miller‐Lotan Henry Furneaux William G. Kaelin Othon Iliopoulos
Topics: Hemoglobin structure and function (96 papers)Neonatal Health and Biochemistry (33 papers)Pancreatic function and diabetes (28 papers)
Cited by: Cancer Research Cell Biology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Circulation
Partner nations: Israel United States Canada

In The Last Decade

Andrew P. Levy

173 papers receiving 9.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia

1995 909 citations Andrew P. Levy, Nina S. Levy et al. profile →
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

1996 713 citations Othon Iliopoulos, Andrew P. Levy et al. profile →
Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR

1998 547 citations Nina S. Levy, Andrew P. Levy et al. profile →
Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia

1996 524 citations Andrew P. Levy, Nina S. Levy et al. profile →

Peers

Countries citing papers authored by Andrew P. Levy

Since Specialization

Citations

This map shows the geographic impact of Andrew P. Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew P. Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew P. Levy more than expected).

Fields of papers citing papers by Andrew P. Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew P. Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew P. Levy. The network helps show where Andrew P. Levy may publish in the future.

Co-authorship network of co-authors of Andrew P. Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew P. Levy. A scholar is included among the top collaborators of Andrew P. Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew P. Levy. Andrew P. Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study 2024 ·Cardiovascular Diabetology ·(unknown),(unknown),Michael P. Bancks,Mark A. Espeland,Judy Bahnson,(unknown),Andrew P. Levy,John L. Sapp,Robin Urquhart,Jinlong Wang,Eric B. Rimm,Leah E. Cahill	2
2	Daily Brief Heat Therapy Reduces Seizures in A350V IQSEC2 Mice and Is Associated with Correction of AMPA Receptor-Mediated Synaptic Dysfunction 2023 ·International Journal of Molecular Sciences ·(unknown),(unknown),(unknown),(unknown),Nina S. Levy,Shlomo Wagner,Shai Netser,Randall S. Walikonis,(unknown),Shai Berlin,Andrew P. Levy	2
3	Relationship Between Time‐Varying Achieved High‐Density Lipoprotein Cholesterol and Risk of Coronary Events Depends on Haptoglobin Phenotype Within the ACCORD Lipid Study 2023 ·Journal of the American Heart Association ·(unknown),(unknown),Pantelis Andreou,Andrew P. Levy,John L. Sapp,Orit Lache,Henry N. Ginsberg,Eric B. Rimm,Christine Herman,Susan Kirkland,Leah E. Cahill	3
4	Structural and functional brain-wide alterations in A350V Iqsec2 mutant mice displaying autistic-like behavior 2021 ·Translational Psychiatry ·(unknown),Eyal Bergmann,Alexandra Kavushansky,Nadav Cohen,Nina S. Levy,Andrew P. Levy,Itamar Kahn	7
5	Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments 2017 ·Expert Opinion on Drug Metabolism & Toxicology ·Elliot Berinstein,Andrew P. Levy	18
6	Evaluation of a course to prepare international students for the United States Medical Licensing Examination step 2 clinical skills exam 2017 ·Journal of Educational Evaluation for Health Professions ·Rachel B. Levine,Andrew P. Levy,(unknown),(unknown),Rebeca Rios,Danelle Cayea	4
7	The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype 2015 ·Journal of the American College of Cardiology ·Leah E. Cahill,Majken K. Jensen,Stephanie E. Chiuve,(unknown),Jennifer K. Pai,Alan Flint,Kenneth J. Mukamal,Kathryn M. Rexrode,Andrew P. Levy,Eric B. Rimm	42
8	Haptoglobin Genotype Is a Consistent Marker of Coronary Heart Disease Risk Among Individuals With Elevated Glycosylated Hemoglobin 2013 ·Journal of the American College of Cardiology ·Leah E. Cahill,Andrew P. Levy,Stephanie E. Chiuve,Majken K. Jensen,Hong Wang,Nawar Shara,Shany Blum,Barbara V. Howard,Jennifer K. Pai,Kenneth J. Mukamal,Kathryn M. Rexrode,Eric B. Rimm	71
9	Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice 2009 ·Cardiovascular Diabetology ·Roy Asaf,Shany Blum,Ariel Roguin,Shiri Kalet-Litman,(unknown),(unknown),Rachel Miller‐Lotan,Andrew P. Levy	13
10	Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice 2006 ·Journal of the American College of Cardiology ·Shany Blum,Roy Asaf,Julia Guetta,Rachel Miller‐Lotan,Rabea Asleh,Ran Kremer,Nina S. Levy,Franklin G. Berger,Doron Aronson,Xiaoming Fu,Renliang Zhang,Stanley L. Hazen,Andrew P. Levy	50
11	Haptoglobin Phenotype, Sleep-Disordered Breathing, and the Prevalence of Cardiovascular Disease: the Sleep Heart Health Study 2005 ·SLEEP ·Andrew P. Levy,Lin Zhang,Rachel Miller‐Lotan,Susan Redline,George O'connor,Stuart F. Quan,Helaine E. Resnick	6
12	New horizons for VEGF. Is there a role for nuclear localization? 2005 ·Acta Histochemica ·Flavio Lejbkowicz,(unknown),Andrew P. Levy	33
13	Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort 2003 ·Atherosclerosis ·Andrew P. Levy,Martin G. Larson,Diane Corey,Rachel Lotan,Joseph A. Vita,Emelia J. Benjamin	48
14	Haptoglobin phenotype in age-related macular degeneration patients 2003 ·American Journal of Ophthalmology ·(unknown),Itzchak Beiran,Rachel Miller‐Lotan,(unknown),(unknown),Benjamin T. Miller,Andrew P. Levy	1
15	Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes 2002 ·Journal of the American College of Cardiology ·Andrew P. Levy,Irit Hochberg,Kathleen Jablonski,Helaine E. Resnick,Elisa T. Lee,Lyle G. Best,Barbara V. Howard	224
16	Bradycardia is associated with development of coronary collateral vessels in humans 2000 ·Coronary Artery Disease ·Sanjay R. Patel,Jeffrey A. Breall,Daniel J. Diver,Bernard J. Gersh,Andrew P. Levy	31
17	Adaptive hypoxic tolerance in the subterranean mole rat Spalax ehrenbergi: the role of vascular endothelial growth factor 1999 ·FEBS Letters ·Aaron Avivi,Murray B. Resnick,Eviatar Nevo,(unknown),Andrew P. Levy	75
18	Hypoxic Regulation of VEGF mRNA Stability by RNA-binding Proteins 1998 ·Trends in Cardiovascular Medicine ·Andrew P. Levy	51
19	Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene 1997 ·Kidney International ·Andrew P. Levy,Nina S. Levy,Othon Iliopoulos,(unknown),William G. Kaelin,Mark A. Goldberg	66
20	An Endothelial Cell Growth Factor from the Mouse Neuroblastoma Cell Line NB41 1989 ·Growth Factors ·Andrew P. Levy,Rafael J. Tamargo,(unknown),Daniel Nathans	61

About Andrew P. Levy

Andrew P. Levy is a scholar working on Cell Biology, Endocrine and Autonomic Systems and Pediatrics, Perinatology and Child Health, having authored 179 papers that have together received 9.9k indexed citations. Recurring topics across this work include Hemoglobin structure and function (96 papers), Neonatal Health and Biochemistry (33 papers) and Pancreatic function and diabetes (28 papers). The work is most often cited by research in Cancer Research (2.5k citations), Cell Biology (2.6k citations) and Molecular Biology (4.6k citations). Andrew P. Levy has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Nina S. Levy, Mark A. Goldberg, Scott A. Wegner, Rabea Asleh, Rachel Miller‐Lotan, Henry Furneaux, William G. Kaelin, Othon Iliopoulos, Cong Jiang and Pedro Moreno. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact